ArticleSubstance use & addiction journal2026
Patient and Provider Perspectives on the Elimination of Urine Drug Testing in Office-Based Addiction Treatment.
Article in Substance use & addiction journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Providers' perspectives on what heroin-assisted treatment ought to be: a qualitative study.BMC health services research · 2026Article
- Lived Experiences of Urine Drug Testing Among Individuals with a Substance Use Disorder: A Punitive or Supportive Intervention?Nursing reports (Pavia, Italy) · 2026Article
- Identifying Optimal Thresholds for Early Opioid Use Frequency in Predicting Buprenorphine Outcomes.The Journal of clinical psychiatry · 2026Article
- Implementation outcomes of video-observed oral fluid self-collection for drug testing in substance use disorder treatment: a pilot study.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundWithin office-based addiction treatment (OBAT) for opioid use disorder, routine urine drug testing (UDT) has been a near-universal practice, despite concerns about increased stigma and limited evidence on improved patient outcomes. During the COVID-19 pandemic, routine UDT was suspended in many settings as care transformed to telehealth, providing an opportunity to explore viewpoints about routine UDT and the implications of its absence.
methodsWe explored patient and provider perspectives through qualitative interviews conducted from May 2021 to May 2022 within an urban, low-threshold OBAT program. Semi-structured interview guides and thematic analysis explored opinions on traditional routine UDT and experiences with its discontinuation during the COVID-19 pandemic.
resultsBased on perspectives of 25 patients and 16 providers, we identified three themes regarding routine UDT and its decreased use during the COVID-19 pandemic: (1) the general utility of UDT within traditional models of care, (2) burdens that routine UDT could present to care engagement, and (3) impacts of UDT on trust within patient-provider relationships.
conclusionsOur findings support the need for reconsideration of routine UDT in OBAT, as well as the needs for improved care standards. Selective use of UDT can be implemented in a patient-centered manner, including offering it upon patient request (eg, for personal "accountability") and discontinuing it when appropriate and to reduce barriers to care. In place of routine UDT, our findings also highlight the need for alternative, non-stigmatizing clinical tools that can support patients and providers within OBAT care settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.